New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:30 EDTVRX, NSRGY, AGNValeant to sell filler, toxin assets to Nestle for $1.4B in cash
Valeant Pharmaceuticals (VRX) announced that it has entered into an agreement with Nestle S.A. (NSRGY) to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. The transaction is subject to customary closing conditions, including clearance or early expiration of the waiting period under the Hart-Scott-Rodino Act and is not contingent upon a successful transaction with Allergan (AGN). Valeant believes that this transaction is extremely attractive both to Valeant and Galderma, and dovetails well with the company's announced plans for a transaction with Allergan.
News For VRX;NSRGY;AGN From The Last 14 Days
Check below for free stories on VRX;NSRGY;AGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 18, 2014
12:51 EDTVRX, AGNKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTAGN, VRXSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
06:41 EDTNSRGYNestle U.S. chocolate goals curbed by Lindt acquisition, Bloomberg says
Nestle, who usually aims to be first or second in all of its divisions, isnít even close in the U.S. chocolate candy industry, where the Swiss firm is shut-out by Mars and Hershey (HSY), reported Bloomberg. When Lindt & Spruengli finalizes its acquisition of Russell Stover Candies, Nestle will fall even deeper behind, by ranking fourth in the U.S. Reference Link
July 17, 2014
16:45 EDTAGN, VRXPershing Square looks to obtain consents for special meeting
Subscribe for More Information
10:20 EDTAGNPershing sees coming 13-Fs to show long-term Allergan holders have been selling
Subscribe for More Information
09:00 EDTAGNAckman says large takeover by Allergan could be 'enormously value destructive'
08:44 EDTAGNPershing says special meeting warranted given 'poor governance' at Allergan
Subscribe for More Information
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:00 EDTVRX, AGNPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTVRX, AGNAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTAGN, VRXPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTAGN, VRXTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:31 EDTAGNPershing Square Capital Management holds analyst/industry conference call
Subscribe for More Information
09:16 EDTAGN, VRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allerganís corporate governance.
08:16 EDTVRX, AGNLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTVRX, AGNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
11:13 EDTAGNPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
July 14, 2014
12:47 EDTVRX, AGNAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:13 EDTVRX, AGNAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTVRX, AGNValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use